Marinus Pharma (MRNS) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Marinus Pharma (MRNS) Reports In-Line Q4 EPS
March 21, 2022 7:25 AM EDTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More